When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
When a seriously ill mature minor and his parent disagree about his receiving an experimental intervention, who should decide what treatment he will receive?
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
Jonathan M. Metzl, MD, PhD and Dorothy E. Roberts, JD
The call for structural competency encourages medicine to broaden its approach to matters of race and culture so that it might better address both individual-level doctor and patient characteristics and institutional factors.
The revisions balance a growing understanding of gender identity disorders and societal views with the need to retain conditions that benefit from intervention and the removal of which would hamper patients’ ability to receive medical treatment.
CBP researchers are challenged to think strategically about ways to convey their accomplishments and educate their non-CBPR peers about the nature of their research, processes not required of traditional researchers.
Elizabeth Lee Daugherty, MD, MPH and Douglas B. White, MD, MA
Opportunities to advance scientific knowledge may arise during humanitarian crises, but their presence does not justify suspension of the ethical foundations governing human subjects research.
Patricia D. Quigley, MD and Megan A. Moreno, MD, MSEd, MPH
Maintaining an adolescent’s confidentiality while answering his or her parents’ questions about their child’s change in mood and behavior can be challenging.